


Trofosfamide

Cat. No.:	HY-119824		
CAS No.:	22089-22-1		
Molecular Formula:	C ₉ H ₁₈ Cl ₃ N ₂ O ₂ P		
Molecular Weight:	323.58		
Target:	Bacterial		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (309.04 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.0904 mL	15.4521 mL	30.9043 mL
	5 mM	0.6181 mL	3.0904 mL	6.1809 mL
	10 mM	0.3090 mL	1.5452 mL	3.0904 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (7.73 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.73 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.73 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Trofosfamide is an orally bioavailable oxazaphosphorine derivative with antineoplastic activity^[1].

CUSTOMER VALIDATION

- Arh Hig Rada Toksikol. 2023 Sep 30;74(3):187-197.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Witte HM, et al. Trofosamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2019 Jan;145(1):129-136.
- [2]. Görn M, et al. A pilot study of docetaxel and trofosamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie. 2008 Apr;31(4):185-9.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA